Insulet Corporation
Financials
Valuation Metrics
Insulet Corporation's Market Cap is $9.74B. At end of 2025 it was $20.00B. Ranked #935 of 3,121 in US market (top 30%), #300 of 1,463 on NASDAQ (top 21%), #66 of 205 in Health Care Equipment & Services (top 32%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.74B | US#935/3,121 Sec#66/205 |
| Revenue | $3.05B | US#1,186/3,121 Sec#71/205 |
| Net Income | $375M | US#986/3,121 Sec#52/205 |
| Total Assets | $3.17B | US#1,782/3,121 Sec#85/205 |
| Net Assets | $1.42B | US#1,513/3,121 Sec#78/205 |
| Employees | 5,400 | US#1,192/3,121 Sec#87/205 |
| Value | ||
| P/E | 25.95x | US#1,452/3,121 Sec#52/205 |
| P/B | 6.85x | US#2,439/3,121 Sec#153/205 |
| PEG | 0.44x | US#569/3,121 Sec#22/205 |
| P/S | 3.19x | US#1,791/3,121 Sec#123/205 |
| EV/EBITDA | 15.94x | US#1,643/3,121 Sec#67/205 |
| FCF Yield | 3.06% | US#1,819/3,121 Sec#104/205 |
| Profitability | ||
| ROE | 26.39% | US#369/3,121 Sec#18/205 |
| ROA | 11.86% | US#349/3,121 Sec#20/205 |
| Op. Margin | 16.89% | US#1,100/3,121 Sec#37/205 |
| Revenue Growth | 29.41% | US#445/3,121 Sec#25/205 |
| Earnings Growth | 58.96% | US#455/3,121 Sec#21/205 |
| Financial Health | ||
| Debt Ratio | 122.55% | US#1,284/3,121 Sec#123/205 |
| Total Debt | $948M | US#1,569/3,121 Sec#85/205 |
| FCF | $298M | US#1,172/3,121 Sec#68/205 |
| Cash | $535M | US#1,032/3,121 Sec#57/205 |
| Current Ratio | 2.48x | US#984/3,121 Sec#97/205 |
| Net Debt/EBITDA | 0.65x | US#832/3,121 Sec#49/205 |
| Performance | ||
| 1Y Return | -57.84% | US#2,982/3,121 Sec#194/205 |
| 1M Return | -7.20% | US#1,610/3,121 Sec#130/205 |
| From 52W High | -60.38% | US#2,917/3,121 Sec#191/205 |
| 1Y MDD | -61.90% | US#2,821/3,121 Sec#177/205 |
| Trading | ||
| Volume | 2,019,567 shares | US#1,284/3,121 Sec#79/205 |
| Trading Value | $285M | US#561/3,121 Sec#47/205 |
| Per Share | ||
| EPS | $5.42 | US#630/3,121 Sec#39/205 |
| BPS | $20.53 | US#1,214/3,121 Sec#68/205 |
Company Info
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.